High-dose injections require medical supervision due to additional risks including kidney stones and drug interactions
It can offer access to treatment for many more of the estimated 200 million Americans who are overweight or obese
Do not report a BMI code without a supporting physician-documented diagnosis (obesity, overweight, or underweight)
[3] [4] Common adverse effects include nausea, vomiting, diarrhea, and constipation, which are generally transient and dose-dependent
However, only a small number of patients were included in the study, and median levels were not elevated even before the commencement of GLP-1 RAs treatment (102)
Furthermore, real-world persistence and adherence for GLP-1 products are major impediments to effective therapy